IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: Michael John ALBERTI, et al.

International Patent Application No.:

PCT/US2004/008301

International Filing Date:

March 18, 2004


Title: CHEMICAL COMPOUNDS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X] Copies of the references are enclosed: Reference #4							
		[] Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) [X] A copy of the International Search Report which issued on International Application No. PCT/US2004/008301 is submitted herewith. All of the publications cited in the International Search						
	[X] A							
]							
		Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.						
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR							
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.						
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).						



0/549972 JC17 Rec'd PCT/PTO 20 SEP 2005

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under					
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the					
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International					
		Publication No.					

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure [] Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Kathryn L. Coulter, Patent Agent Registration No. 45,889

Kathyn L. Coulter

Date: <u>September</u> 20,2005 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1467

Facsimile: (919) 483-5730

2

FORM PTO INFORMA		ISCLOSURE ST	ATEMENT		ATTORNEY DOCKET		SERIAD NO. 15 4997	
					APPLICANT: Michael John ALBERTI, et al.			
					FILING DATE:		GROUP	
					Concurrently He	rewith	To be assigned	
			U.S. F	ATENT D	OCUMENTS			Filing Date
Examiner Initials		Patent Number_	Issue Date		Name	Class	Subclass	If Appropriate
	1.	10/481,699	12/22/2003	BERG, e				
	2.	10/508,592	09/22/2004	ALBERTI, et al.				
	3.	10/508,760	09/22/2004	BAILEY,	et al.			
					-1.			İ
			ļ					ļ
				<u> </u>				ļ
	<u> </u>		<u> </u>					<u> </u>
		····		ontinue on j				
	1 1			N PATEN	r documents			T = 1
		Document Number	Publication Date			Class	Subclass	Translation Yes No
	4.	03/066629	08/14/2003	PCT				
	\vdash							
			<u> </u>					
			ļ					
			 	-				
			L			· L	1	<u> </u>
		OTHER DOCUM		ontinue on j	oage Title, Journal-Da	As Dans Name	E4- \	
	<u> </u>	OTHER DOCUM	VIEN 15 (Includi	ng Author,	Title, Journal-Da	ate, Page Numb	er, Etc.)	
	 	2 ⁻⁰ - 110						
	 				<u></u>			

			* * * * * * * * * * * * * * * * * * * *				···	
								
	\sqcup							
	$oxed{oxed}$							
BU				Continue on	page	·¥		
EXAMINER						DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.